Scantox A/S, a leading Nordic GLP-compliant pre-clinical contract research organization, headquartered in Denmark and since 2021 owned by Impilo, recently announced the acquisition of Q&Q Labs AB located in Gothenburg, Sweden.
Q&Q is a leading provider of tailor made bioanalytical services and brings a highly complementary service offering to Scantox’s stronghold in pharmacology and regulatory toxicology. Through the acquisition, Scantox will boost its analytical capabilities, scientific expertise and capacity with the aim of providing an even more comprehensive portfolio of drug development services to meet the evolving needs of its growing customer base.
Scantox CEO on the deal
Jeanet Løgsted, CEO of Scantox, comments: “Scantox embarked on an ambitious growth journey when we acquired the first two international companies last year, and we are thrilled to now expand our Group further with the acquisition of Q&Q. We welcome a company known for their solid expertise within the field of bioanalysis. This aligns perfectly with the current and future direction of Scantox, where a constant focus on the highest scientific and technical quality, as well as ethical standards, is at the core. The new expansion will make us well positioned to meet current and future market requirements, as a preferred service provider and partner to our growing customer portfolio of pharma, biotech, and medical device companies, paving the way for strong continued profitable growth.”
With this acquisition Scantox has nearly 200 employees across four sites.
Q&Q CEO on the new deal
Rickard Wahlström, CEO of Q&Q: “We are looking forward to leveraging the synergies across Scantox to deliver the best customized solutions to the market. Our expertise and set up will fit very well into the Scantox portfolio, and I am convinced that current and new customers will benefit from the full service offering for their pre-clinical development requirements.”
For more acquisition related news in the medical field:
Invitae welcomes Robert Guigley as Chief Commercial Officer
Harrison.ai appoints Robyn Denholm as Board Director
